Three-dimensional magnetic resonance elastography combining proton-density fat fraction precisely identifies metabolic dysfunction-associated steatohepatitis with significant fibrosis

• Published in: Magnetic resonance imaging Vol. 104; pp. 1 - 8
• Main Authors: Lin, Huimin, Qiu, Suhao, Yang, Yanzhao, Yang, Chunxue, Shen, Zhehan, Chen, Yu, Zhang, Zhihan, Feng, Yuan, Yan, Fuhua
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01-12-2023
• Subjects: Adipose Tissue - diagnostic imaging; Adipose Tissue - pathology; Animals; Elasticity Imaging Techniques - methods; Fatty Liver - diagnostic imaging; Fatty Liver - pathology; Imaging, Three-Dimensional; Liver; Liver - diagnostic imaging; Liver - pathology; Liver Cirrhosis - diagnostic imaging; Liver Cirrhosis - pathology; Magnetic resonance elastography; Magnetic Resonance Imaging - methods; Male; Metabolic dysfunction-associated steatohepatitis; Metabolic dysfunction-associated steatotic liver disease; Proton-density fat fraction; Protons; Rabbits; ROC Curve; CRP; LN; Metabolic dysfunction-associated steatotic liver disease; NRI; Liver; CK18-M30; AUROC; MASH; DR; PDFF; Magnetic resonance elastography; Fibro-MASH; Proton-density fat fraction; SS; Metabolic dysfunction-associated steatohepatitis; AST; CI; MMP3; ROC; ICC; MASLD; OSS-SNR; ROI; MEG; TE; TNF-α; HA; MAS; 3D-MRE; EPI
• ISSN: 0730-725X; 1873-5894; 1873-5894
• DOI: 10.1016/j.mri.2023.07.017

Patients with metabolic dysfunction-associated steatohepatitis (MASH) and significant fibrosis (fibrosis stage≥2), known as Fibro-MASH, are at increased risk of liver-related outcomes and lower rates of spontaneous disease regression. The aim was to investigate three-dimensional MR elastography (3D-MRE) combining proton-density fat fraction (PDFF) as a means of identifying Fibro-MASH.
Forty-eight New Zealand rabbits were fed a high-fat/cholesterol or standard diet to obtain different disease activity and fibrosis stages. Shear stiffness (SS) and Damping Ratio (DR) were derived from 3D-MRE, whereas PDFF was from a volumetric 3D imaging sequence. Steatosis grade, metabolic dysfunction-associated steatotic liver disease activity score (MAS), and fibrosis stage were diagnosed histologically. Serum markers of fibrosis and inflammation were also measured. Correlation and comparison analysis, Receiver operating characteristic curves (ROC), Delong test, logistic regression analysis, and Net reclassification improvement (NRI) were performed.
PDFF correlated with steatosis grade (rho = 0.853). SS increased with developed liver fibrosis (rho = 0.837). DR correlated with MAS grade (rho = 0.678). The areas under the ROC (AUROCs) of SS for fibrosis grading were 0.961 and 0.953 for ≥F2, and ≥ F3, respectively. All the biochemical parameters were considered but excluded from the logistic regression analysis to identify Fibro-MASH. FF, SS, and DR were finally included in the further analysis. The three-parameter model combining PDFF, SS, and DR showed significant improvement in NRI over the model combining SS and PDFF (AUROC 0.973 vs. 0.906, P = 0.081; NRI 0.28, P < 0.05).
3D-MRE combining PDFF may characterize the state of fat content, disease activity and fibrosis, thus precisely identify Fibro-MASH.